Next Article in Journal
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
Next Article in Special Issue
Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity
Previous Article in Journal
Gastric Cancer Staging: Is It Time for Magnetic Resonance Imaging?
Previous Article in Special Issue
Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination
Article

Spectrum-Wide Exploration of Human Adenoviruses for Breast Cancer Therapy

1
Virology and Microbiology, Center for Biomedical Education and Research (ZBAF), Department of Human Medicine, Faculty of Health, Witten/Herdecke University, 58453 Witten, Germany
2
Institute of Immunology, Center for Biomedical Education and Research (ZBAF), Department of Human Medicine, Faculty of Health, Witten/Herdecke University, 58453 Witten, Germany
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this paper.
Cancers 2020, 12(6), 1403; https://doi.org/10.3390/cancers12061403
Received: 3 April 2020 / Revised: 22 May 2020 / Accepted: 25 May 2020 / Published: 29 May 2020
(This article belongs to the Special Issue The Role of Adenovirus in Cancer Therapy)
Oncolytic adenoviruses (Ads) are promising tools for cancer therapeutics. However, most Ad-based therapies utilize Ad type 5 (Ad5), which displays unsatisfying efficiency in clinical trials, partly due to the low expression levels of its primary coxsackievirus and adenovirus receptor (CAR) on tumor cells. Since the efficacy of virotherapy strongly relies on efficient transduction of targeted tumor cells, initial screening of a broad range of viral agents to identify the most effective vehicles is essential. Using a novel Ad library consisting of numerous human Ads representing known Ad species, we evaluated the transduction efficiencies in four breast cancer (BC) cell lines. For each cell line over 20 Ad types were screened in a high-throughput manner based on reporter assays. Ad types featuring high transduction efficiencies were further investigated with respect to the percentage of transgene-positive cells and efficiencies of cellular entry in individual cell lines. Additionally, oncolytic assay was performed to test tumor cell lysis efficacy of selected Ad types. We found that all analyzed BC cell lines show low expression levels of CAR, while alternative receptors such as CD46, DSG-2, and integrins were also detected. We identified Ad3, Ad35, Ad37, and Ad52 as potential candidates for BC virotherapy. View Full-Text
Keywords: adenovirus; adenovirus receptors; breast cancer; broad spectrum; cellular entry; high-throughput screening; virotherapy adenovirus; adenovirus receptors; breast cancer; broad spectrum; cellular entry; high-throughput screening; virotherapy
Show Figures

Figure 1

MDPI and ACS Style

Mach, N.; Gao, J.; Schaffarczyk, L.; Janz, S.; Ehrke-Schulz, E.; Dittmar, T.; Ehrhardt, A.; Zhang, W. Spectrum-Wide Exploration of Human Adenoviruses for Breast Cancer Therapy. Cancers 2020, 12, 1403. https://doi.org/10.3390/cancers12061403

AMA Style

Mach N, Gao J, Schaffarczyk L, Janz S, Ehrke-Schulz E, Dittmar T, Ehrhardt A, Zhang W. Spectrum-Wide Exploration of Human Adenoviruses for Breast Cancer Therapy. Cancers. 2020; 12(6):1403. https://doi.org/10.3390/cancers12061403

Chicago/Turabian Style

Mach, Nicolas, Jian Gao, Lukas Schaffarczyk, Sebastian Janz, Eric Ehrke-Schulz, Thomas Dittmar, Anja Ehrhardt, and Wenli Zhang. 2020. "Spectrum-Wide Exploration of Human Adenoviruses for Breast Cancer Therapy" Cancers 12, no. 6: 1403. https://doi.org/10.3390/cancers12061403

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop